Emergent BioSolutions to lay off 400, reduce operations in Baltimore

Gaithersburg biotech Emergent BioSolutions (NYSE: EBS) said Tuesday it is significantly reducing its contract development and manufacturing business in a cost-savings measure that will result in about 400 layoffs. Emergent said the move is being made to focus on its core products business, which includes medical countermeasures and opioid overdose antidote Narcan.